This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.
Carlos Dzik, MD
Advertisement
Articles by Carlos Dzik, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
What Are the Top Takeaways for Neuroendocrine Carcinoma From 2026 ESMO?
4
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
5